Key result
High circulating ADMA after CAG or PCI is linked to ~2.1-fold higher all-cause mortality.
Why the study?
Despite procedural advances, CAD remains associated with residual risk after invasive investigation and revascularization. This review critically synthesizes evidence linking circulating ADMA to coronary anatomy, plaque characteristics, cardiovascular outcomes, and restenosis in patients undergoing CAG or PCI, with special attention to T2DM.
Does elevated circulating asymmetric dimethylarginine (ADMA) predict adverse cardiovascular outcomes and restenosis in patients undergoing coronary angiography or percutaneous coronary intervention?
Does elevated circulating asymmetric dimethylarginine (ADMA) predict adverse cardiovascular outcomes and restenosis in patients undergoing coronary angiography or percutaneous coronary intervention?
Answers are grounded in this paper and cite their sources.
Although elevated circulating ADMA frequently correlates with adverse cardiovascular outcomes and restenosis after coronary angiography or PCI, variability across studies and lack of assay standardization currently limit its actionable clinical utility.
Background. Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of nitric oxide synthase and a candidate marker of impaired endothelial nitric oxide signaling. Despite procedural advances, coronary artery disease (CAD) remains associated with residual risk after invasive investigation and revascularization. Objective. To critically synthesize evidence linking circulating ADMA to coronary anatomy, plaque characteristics, cardiovascular outcomes, and restenosis in patients undergoing coronary angiography (CAG) or percutaneous coronary intervention (PCI), with special attention to type 2 diabetes mellitus (T2DM). Evidence synthesis. In a meta-analysis of nine prospective CAG/PCI studies (6,374 participants), high versus low ADMA was associated with all-cause mortality (adjusted pooled RR 2.11, 95% CI 1.38–3.21), cardiovascular mortality (2.95, 1.14–7.68), major adverse cardiovascular events (2.10, 1.35–3.27), and restenosis (4.57, 2.52–8.30) [13]. However, other prospective cohorts yielded weaker or null associations for recurrent cardiovascular events [24], and findings vary by population, endpoint, kidney function, and analytical method [14–16,19]. A 2023 optical coherence tomography study associated higher ADMA with plaque vulnerability and subsequent events after PCI [12]. Conclusions. ADMA is a biologically credible research biomarker and frequently correlates with adverse prognosis, but independent association is not synonymous with improved prediction or actionable clinical benefit. Contemporary, assay-standardized, externally validated studies in defined PCI populations, particularly patients with T2DM, are needed.
No takes yet. Share an insight, caveat, or question.
Shamansurova et al. (2026) conducted a review in Coronary artery disease undergoing coronary angiography or percutaneous coronary intervention (n=6,374). High circulating asymmetric dimethylarginine (ADMA) vs. Low circulating asymmetric dimethylarginine (ADMA) was evaluated on All-cause mortality (RR 2.11, 95% CI 1.38-3.21). High vs low circulating ADMA after CAG/PCI is associated with increased all-cause mortality and major cardiovascular events.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: